Sunday, May 5, 2024
Home Psychedelic Stock Review Page 6

Psychedelic Stock Review

    Most popular

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    2022 Watch List Editor / Curator -
    TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

    Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?

    CoronaVirus Editor / Curator -
    Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...

    Revive’s Quarterly Report, Discussion, and a Video!

    Superbug News - CoronaVirus Watch List Editor / Curator -
    With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....

    Ehave’s Mobile Ketamine Clinic, Rolling into Town.

    Psychedelic Stock Review Editor / Curator -
    Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...
    1...456Page 6 of 6

    Latest article

    We’re in Tampa for the Kentucky Derby.

    2024 Watch List Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.